BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 8994300)

  • 1. A critical appraisal of the value of the mouse cancer bioassay in safety assessment.
    Alden CL; Smith PF; Piper CE; Brej L
    Toxicol Pathol; 1996; 24(6):722-5. PubMed ID: 8994300
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mouse-specific carcinogens: an assessment of hazard and significance for validation of short-term carcinogenicity bioassays in transgenic mice.
    Battershill JM; Fielder RJ
    Hum Exp Toxicol; 1998 Apr; 17(4):193-205. PubMed ID: 9617631
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Are tumor incidence rates from chronic bioassays telling us what we need to know about carcinogens?
    Gaylor DW
    Regul Toxicol Pharmacol; 2005 Mar; 41(2):128-33. PubMed ID: 15698536
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expectations for transgenic rodent cancer bioassay models.
    Ashby J
    Toxicol Pathol; 2001; 29 Suppl():177-82. PubMed ID: 11695555
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neonatal mouse assay for tumorigenicity: alternative to the chronic rodent bioassay.
    Flammang TJ; Tungeln LS; Kadlubar FF; Fu PP
    Regul Toxicol Pharmacol; 1997 Oct; 26(2):230-40. PubMed ID: 9356286
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A data-based assessment of alternative strategies for identification of potential human cancer hazards.
    Boobis AR; Cohen SM; Doerrer NG; Galloway SM; Haley PJ; Hard GC; Hess FG; Macdonald JS; Thibault S; Wolf DC; Wright J
    Toxicol Pathol; 2009 Oct; 37(6):714-32. PubMed ID: 19700658
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alternatives to the 2-species bioassay for the identification of potential human carcinogens.
    Ashby J
    Hum Exp Toxicol; 1996 Mar; 15(3):183-202. PubMed ID: 8839204
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Tg rasH2 mouse in cancer hazard identification.
    Morton D; Alden CL; Roth AJ; Usui T
    Toxicol Pathol; 2002; 30(1):139-46. PubMed ID: 11890467
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A perspective on current and future uses of alternative models for carcinogenicity testing.
    Goodman JI
    Toxicol Pathol; 2001; 29 Suppl():173-6. PubMed ID: 11695554
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of the utility of the lifetime mouse bioassay in the identification of cancer hazards for humans.
    Osimitz TG; Droege W; Boobis AR; Lake BG
    Food Chem Toxicol; 2013 Oct; 60():550-62. PubMed ID: 23954551
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alternative models for carcinogenicity testing: weight of evidence evaluations across models.
    Cohen SM
    Toxicol Pathol; 2001; 29 Suppl():183-90. PubMed ID: 11695556
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of transgenic animals for carcinogenicity testing: considerations and implications for risk assessment.
    Gulezian D; Jacobson-Kram D; McCullough CB; Olson H; Recio L; Robinson D; Storer R; Tennant R; Ward JM; Neumann DA
    Toxicol Pathol; 2000; 28(3):482-99. PubMed ID: 10862569
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evolution of the uses of rats and mice for assessing carcinogenic risk from chemicals in humans.
    Ward JM
    Asian Pac J Cancer Prev; 2010; 11(1):18. PubMed ID: 20593921
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predicting the carcinogenicity of chemicals in humans from rodent bioassay data.
    Goodman G; Wilson R
    Environ Health Perspect; 1991 Aug; 94():195-218. PubMed ID: 1954931
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Toxicokinetic and mechanistic considerations in the interpretation of the rodent bioassay.
    MacDonald JS; Lankas GR; Morrissey RE
    Toxicol Pathol; 1994; 22(2):124-40. PubMed ID: 7973360
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessment of human cancer risk: challenges for alternative approaches.
    Omenn GS
    Toxicol Pathol; 2001; 29 Suppl():5-12. PubMed ID: 11695561
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prediction of carcinogenicity from two versus four sex-species groups in the carcinogenic potency database.
    Gold LS; Slone TH
    J Toxicol Environ Health; 1993 May; 39(1):143-57. PubMed ID: 8492327
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An enhanced thirteen-week bioassay as an alternative for screening for carcinogenesis factors.
    Cohen SM
    Asian Pac J Cancer Prev; 2010; 11(1):15-7. PubMed ID: 20593920
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interspecies extrapolation in carcinogenesis: prediction between rats and mice.
    Gold LS; Bernstein L; Magaw R; Slone TH
    Environ Health Perspect; 1989 May; 81():211-9. PubMed ID: 2759059
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The mouse carcinogenicity study is no longer a scientifically justifiable core data requirement for the safety assessment of pesticides.
    Billington R; Lewis RW; Mehta JM; Dewhurst I
    Crit Rev Toxicol; 2010 Jan; 40(1):35-49. PubMed ID: 20144135
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.